The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder. Serotonin (5-HT) is known to play a physiological and pathophysiological role in the regulation of gastrointestinal function. In experimental studies, 5-HT 3 receptor antagonists have been reported to slow colon transit, to blunt gastrocolonic reflex, and to reduce rectal sensitivity. Alosetron and cilansetron, potent and selective 5-HT 3 receptor antagonists, have proven efficacy in the treatment of IBS with diarrhea (IBS-D). However, alosetron was voluntarily withdrawn due to postmarketing reports of ischemic colitis and complications of constipation, and cilansetron was never marketed. Currently alosetron is available under a risk management program for women with severe IBS-D. Ramosetron is another potent and selective 5-HT 3 receptor antagonist, which has been marketed in Japan, South Korea, and Taiwan. In animal studies, ramosetron reduced defecation induced by corticotrophin-releasing hormone and had inhibitory effects on colonic nociception. In two randomized controlled studies including 957 patients with IBS-D, ramosetron increased monthly responder rates of patient-reported global assessment of IBS symptom relief compared with placebo. Ramosetron was also as effective as mebeverine in male patients with IBS-D. In a recent randomized controlled trial with 343 male patients with IBS-D, ramosetron has proved effective in improving stool consistency, relieving abdominal pain/discomfort, and improving health-related quality of life. Regarding safety, ramosetron is associated with a lower incidence of constipation compared with other 5-HT 3 receptor antagonists and has not been associated with ischemic colitis. Although further large prospective studies are needed to assess whether ramosetron is effective for female patients with IBS-D and to evaluate its long-term safety, ramosetron appears to be one of the most promising agents for patients with IBS-D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drugs acting as antagonists at the 5-HT 3 receptor are also licensed for IBS-D. These include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral hypersensitivity and alter rectal compliance. [231][232][233]”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [232]
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155 · cited 2×
“[Lovell and Ford, 2012].”
BackgroundGershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
The Enteric Nervous System: A Second Brain
Gershon, M. D. (1999) · Hospital Practice · doi:10.3810/hp.1999.07.153 · Cited by 319 · cited 1×
“When secreted, 5-HT can activate 5-HT3 receptors located on intrinsic primary afferent neurons with submucosal terminals, thus initiating the peristaltic reflex and modulating intestinal secretion [Gershon, 1999; Cooke, 2000].”
BackgroundPeripheral mechanisms in irritable bowel syndrome
Camilleri, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1207068 · Cited by 300 · cited 1×
“…bowel motility, visceral hypersensitivity, mucosal immune activation, increased mucosal permeability, enteric neuromuscular dysfunction, abnormal brain–gut interactions, alteration in the gut microbiome, and psychological disturbance have been hypothesized [Camilleri, 2005, 2012; Hasler, 2011].”
BackgroundSex-related differences in IBS patients: central processing of visceral stimuli
Naliboff, B. D., Berman, S., Chang, L., Derbyshire, S. W. G., Suyenobu, B., Vogt, B. A., Mandelkern, M., & Mayer, E. A. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00400-1 · Cited by 292 · cited 1×
“Male and female patients with IBS differ in their brain response to a visceral stimulus and a condition [Berman et al. 2000; Naliboff et al. 2003].”
BackgroundRole of serotonin in the pathophysiology of the irritable bowel syndrome
Crowell, M. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705762 · Cited by 291
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome
Camilleri, M., Atanasova, E., Carlson, P. J., Ahmad, U., Kim, H. J., Viramontes, B. E., Mckinzie, S., & Urrutia, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.34780 · Cited by 285
Peripheral Mechanisms in Irritable Bowel Syndrome
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214185 · Cited by 280
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246 · cited 2×
“Recently, a large RCT of 120 patients with IBS-D showed that ondansetron of 4 mg for 5 weeks improves stool consistency, reduced urgency, frequency, and bloating, but does not reduce abdominal pain [Garsed et al. 2014].”
Background
Research works printed but not linked: 1
- Bjornsson E., 1998, Am J Physiol, 275, G498
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome
Barbara, G., Grover, M., Bercik, P., Corsetti, M., Ghoshal, U. C., Ohman, L., & Rajilić-Stojanović, M. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.07.011 · Cited by 281
“Mucosal IL-1b mRNA expression has been reported to be higher in PI-IBS patients than in healthy individuals.(59) Furthermore, an increased mucosal level of interferon gamma and a decreased level of IL-10 were reported in PI-IBS patients, suggesting involvement of the Th1”
BackgroundResultBlack, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12259 · Cited by 146
“Ramosetron, a more recently developed 5‐HT3 receptor antagonist, was tested in IBS‐D and has been demonstrated to be superior to placebo in treating both diarrhoea and abdominal pain.(225) The drug is currently licenced only in Asia at a dosage of 2.”
MethodNeurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management
Gros, M., Gros, B., Mesonero, J. E., & Latorre, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153429 · Cited by 125
Metadata
- Authors
- Min, Y. W., & Rhee, P.-L.
- Affiliations
- Samsung Medical Center (KR)
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2015-02-24
- Volume
- 8
- Issue
- 3
- Pages
- 136-142
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- PMC
- PMC4416292
- OpenAlex
- W2089464643
- Cited by
- 30
- References
- 49
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 2
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Gastroenterology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- ramosetron, irritable bowel syndrome with diarrhea, 5-HT3 receptor antagonists, serotonin, alosetron, ischemic colitis, constipation, stool consistency, abdominal pain, health-related quality of life, mebeverine, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). https://app.cochat.ai/papers/10.1177/1756283x15572580
- The paper
- Min, Y. W., & Rhee, P.-L. (2015). The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x15572580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.